Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.60 |
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.53 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.52 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.52 |
| ▸ | PKLR | P30613 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072749 | 0.91 | MMP2 (0.60) | MMP2SLC40A1GAAMEN1KMT2A | |
| SCHEMBL5597927 | 0.86 | MEN1 (0.65) | MMP2SLC40A1GAAMEN1KMT2A | |
| SCHEMBL5072751 | 0.84 | MEN1 (0.71) | MMP2SLC40A1GAAMEN1KMT2A | |
| SCHEMBL3982318 | 0.84 | METAP2 (0.60) | MMP2SLC40A1GAAMEN1KMT2A | |
| SCHEMBL14301206 | 0.84 | MEN1 (0.67) | MMP2SLC40A1GAAMEN1KMT2A | |
| SCHEMBL14392443 | 0.83 | KCNA5 (0.62) | MMP2SLC40A1GAAMEN1KMT2A | |
| SCHEMBL5074835 | 0.83 | FABP1 (0.54) | MMP2SLC40A1GAAMEN1KMT2A | |
| SCHEMBL22315265 | 0.82 | ATM (0.74) | SLC40A1GAAMEN1KMT2AATM | |
| SCHEMBL15689758 | 0.82 | PKLR (0.62) | MMP2SLC40A1GAAMEN1KMT2A | |
| SCHEMBL5074826 | 0.81 | KCNA5 (0.57) | MMP2SLC40A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106099-B2 | 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide or other phenylcarboxamide derivatives with dofetilide, ibutilide, almokalant, sotalol, azimilide, amiodarone, E4031, clofilium, ambasilide, MS551, tedisamil, bertosamil and quinidine as IKr chahel blocker | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| CN-101636154-B | Inhibitors of the TASK-1 and TASK-3 ion channels | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-12-14 | — | — | CN | disclosed |
| EP-1605976-B1 | PHENYLCARBOXYL ACID AMIDES AND IK r CHANNEL INHIBITORS COMBINATION AND THE USE THEREOF FOR TREATING ATRIAL ARRHYTHMIA | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-02-24 | — | — | EP | disclosed |
| CN-101636154-A | Inhibitors of the TASK-1 and TASK-3 ion channels | SANOFI AVENTIS DEUTSCHLAND | 2010-01-27 | — | — | CN | disclosed |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| EP-2012758-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | Sanofi-Aventis Deutschland GmbH (DE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1399423-B9 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1399423-B9 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1399423-B1 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-14 | — | — | EP | disclosed |
| EP-1399423-B1 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-14 | — | — | EP | disclosed |
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-23 | — | — | US | disclosed |
| US-6903216-B2 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| WO-2005025674-A1 | COMBINATION OF PHENYLCARBOXAMIDES WITH BETA-ADRENERGIC RECEPTOR BLOCKERS AND USE THEREOF FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004082716-A1 | PHENYLCARBOXYL ACID AMIDES AND IKr CHANNEL INHIBITORS COMBINATION AND THE USE THEREOF FOR TREATING ATRIAL ARRHYTHMIA | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | WO | disclosed |
| CN-1529695-A | Anthranilic acid amides with heteroarylsulfonyl side chains, method for the production thereof, use thereof as medicaments or diagnostic agents, and pharmaceutical preparations containing said compounds | ������ҽҩ�¹�����˾ | 2004-09-15 | — | — | CN | disclosed |
| EP-1399423-A2 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-19 | — | — | US | disclosed |
| WO-2002100825-A2 | ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, AND USE THEREOF AS ANTIARRHYTHMIC ACTIVE SUBSTANCES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | KCNH2, KCNJ2, KCNH1 | MMP2 4571/4885SLC40A1 3694/4885GAA 4490/4885 |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | SCN5A, KCNH1, KCNA5 | MMP2 4467/4885SLC40A1 2813/4885GAA 4601/4885 |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | KCNN3, CACNA1I, KCNN1 | MMP2 3613/4885SLC40A1 3277/4885GAA 1744/4885 |
| US-20050137200-A1 | Potassium channel modulators; antiarrhythmia agents | KCNJ2, KCNQ5, KCNH1 | MMP2 4252/4885SLC40A1 1934/4885GAA 3975/4885 |
| US-20030114499-A1 | Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use | KCNJ2, KCNQ5, KCNH1 | MMP2 4149/4885SLC40A1 2175/4885GAA 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.